🟢 Immunitybio is trading 5.65% up today after FDA expanded ANKTIVA approval for bladder cancer treatment

Immunitybio is trading at $10.47 (+5.65%) after the FDA expanded ANKTIVA’s approval to cover BCG-unresponsive bladder cancer with papillary-only tumors.

• The label expansion, announced October 14, 2026, broadens the treatment’s eligible patient population and serves as a significant company-specific catalyst.
• Following the initial FDA news on October 14, shares closed at $9.91, representing a 1.12% gain during that session.